Skip to main content
STADA Arzneimittel AG logo

STADA Arzneimittel AG — Investor Relations & Filings

Ticker · SAZ ISIN · DE0007251803 LEI · 529900FMTTLMH0P0DL10 HM Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2015-11-11 Board/Management Inform…
Country DE Germany
Listing HM SAZ

About STADA Arzneimittel AG

https://www.stada.com/

STADA Arzneimittel AG is a pharmaceutical company that operates on a three-pillar strategy consisting of generics, consumer healthcare products, and specialty pharmaceuticals. The company is a leading manufacturer of affordable generic medicines, which have been a core part of its business since its founding. In the consumer healthcare segment, STADA markets a wide portfolio of over-the-counter (OTC) products and well-known brands. The specialty pharmaceuticals division focuses on developing and marketing value-added medicines, including an expanding portfolio of biosimilars for therapeutic areas such as oncology, immunology, and bone health.

Recent filings

Filing Released Lang Actions
STADA Arzneimittel AG: Appointment of Helmut Kraft as Chief Financial Officer extended
Board/Management Information Classification · 100% confidence The document is a press release announcing the extension of the appointment for Helmut Kraft, the Chief Financial Officer (CFO), of STADA Arzneimittel AG. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information' (MANG). The text explicitly mentions the Supervisory Board extending the appointment of the CFO, which is a management change.
2015-11-11 English
Declaration of Voting Results & Voting Rights Announcements 2015
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Veröffentlichung einer Stimmrechtsmitteilung' (Publication of a voting rights notification) according to German securities law (§ 26 Abs. 1 WpHG and § 25a Abs. 1 WpHG). This type of filing reports changes in significant share ownership thresholds or voting rights held by an entity. This directly corresponds to the definition of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2015-10-09 German
Declaration of Voting Results & Voting Rights Announcements 2015
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Veröffentlichung einer Stimmrechtsmitteilung' (Publication of a voting rights notification) according to German securities law (§ 25a Abs. 1 WpHG). It details a change in the voting rights share of Société Générale S.A. in STADA Arzneimittel AG, specifically an 'Unterschreitung' (crossing below) the 10% threshold. This type of mandatory disclosure regarding changes in major shareholdings or voting rights directly corresponds to the definition of Major Shareholding Notification (MRQ). Although the document mentions 'Voting Rights Announcements' in the header, the content is a specific notification about a shareholder crossing a threshold, which aligns best with MRQ.
2015-09-25 German
STADA Arzneimittel AG: Clarification of the media's incorrect presentation of the remuneration for the STADA Chairman of the Executive Board
Remuneration Information Classification · 95% confidence The document is a press release from STADA Arzneimittel AG titled "Clarification of the media’s incorrect presentation of the remuneration for the STADA Chairman of the Executive Board." The core subject matter is the compensation and salary figures for the Executive Board Chairman, which directly relates to executive pay disclosure. Among the provided definitions, 'Remuneration Information (Code: DEF 14A)' is the most specific category for reports detailing compensation for top executives and directors. Although this is a clarification press release rather than the formal DEF 14A filing itself, the subject matter is unequivocally remuneration disclosure, making DEF 14A the best fit over a general Regulatory Filing (RNS). The document length is short (3778 chars), but it is providing substantive clarification on remuneration figures, not just announcing that a report is available.
2015-09-10 English
STADA Arzneimittel AG: Executive Board contract of Chairman of the Executive Board Hartmut Retzlaff extended by five years
Board/Management Information Classification · 98% confidence The document is a press release announcing the extension of the contract for the Chairman of the Executive Board, Hartmut Retzlaff, for five years. This type of announcement concerns changes in senior management personnel. Based on the provided definitions, the category 'Board/Management Information (Code: MANG)' is the most appropriate fit, as it covers 'Announcement of changes in the company's board of directors or senior management.' The document is clearly not an Annual Report (10-K), Earnings Release (ER), or a general Regulatory Filing (RNS), but a specific personnel announcement.
2015-09-08 English
Q2 Report 2015
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT ON THE FIRST SIX MONTHS 2015' and contains comprehensive financial data, including consolidated key figures, sales development, and earnings development for the first half of the fiscal year. It is a substantive financial report rather than an announcement or a certification, fitting the definition of an Interim/Quarterly Report. H1 2015
2015-08-07 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.